New Options for the Treatment of Invasive Fungal Infections

Seminars in Oncology

Volumn 31, Issue 2 SUPPL. 4, 2004, Pages 91-98

  Rubin, Zachary A ^a   Somani, Jyoti ^a,b  

^a EMORY UNIVERSITY   (United States)

^b WMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; ECHINOCANDIN B DERIVATIVE; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; NELFINAVIR; NEVIRAPINE; PHENYTOIN; POSACONAZOLE; RIFAMPICIN; TACROLIMUS; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLUS; BRONCHOSPASM; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; DISEASE COURSE; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; FACE EDEMA; FLUSHING; HALLUCINATION; HEADACHE; HOSPITAL INFECTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOULD; MYCOSIS; NAUSEA; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RASH; VISUAL DISORDER; WHEEZING;

EID: 2342661228     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.02.020     Document Type: Conference Paper

References (43)

1. Pfaller MA, Jones RN, Doern GV, et al: bloodstream infections due to Candida Species: SENTRY Antimicrobial surveillance program in North America 1997-1998. Antimicrob Agents Chemother 44:747-751, 2000
2. Trick W, Fridkin S, Edwards J: secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35:627-630, 2002
3. Pfaller MA, Jones RN, Messer SA, et al: National surveillance of nosocomial blood stream infection due to candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 31:327-332, 1998
4. Center for Disease Control: National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 27:520-532, 1999
5. Anaissie E, Vartivarian S, Abi-Said D, et al: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 101:170-176, 1996
6. Rex J, Bennett J, Sugar A: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331: 1325-1330, 1994
7. Laverdiere M, Hoban D, Restieri C, et al: In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antibiot Chemother 50:119-123, 2002
8. Nelson P, Lozano-Chiu M, Rex JH: In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: Influence of assay conditions. J Med Vet Mycol 35:285-287, 1997
9. Sutton D, Rinaldi M, Fothergill A: In vitro activity of the echinocandin caspofungin (MK-0991) against refractory clinical isolates of candida and aspergillus species. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001 (abstr 113)
10. Pfaller M, Jones R, Doem G: International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis 35:19-25, 1999
11. Espinel-Ingroff A: Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36:2950-2956, 1998
12. Mora-Duarte J, Betts R, Rotstein C, et al: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029, 2002
13. Marr KA, Carter RA, Crippa F, et al: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909-917, 2002
14. Ascioglu S, Rex J, de Pauw B, et al: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An International Consensus. Clin Infect Dis 34:7-14, 2002
15. Sulahian A, Boutboul F, Ribaud P, et al: Value of antigen detection using in enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91:311-318, 2001
16. Maertens J, Verhaegen J, Lagrou K, et al: Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 97:1604-1610, 2001
17. Bretagne S, Costa J, Bart-Delabesse E, et al: Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 26:1407-1412, 1998
18. Denning D: Therapeutic outcomes of invasive aspergillosis. Clin Infect Dis 23:608-615, 1996
19. Lin S, Schranz J, Teutsch S: Aspergillus case-fatality rate: Systematic review of the literature. Clin Infect Dis 32: 358-366, 2001
20. Walsh T, Hiemenz J, Seibel NL, et al: Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383-1396, 1998
21. Denning D, Lee J, Hostetler J, et al: NIAID Mycoses Study Group. Multicenter Trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135-144, 1994
22. Stevens D, Lee J: Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 157:1857-1862, 1997
23. Herbrecht R, Denning D, Patterson T, et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415, 2002
24. Pai M, Allen S: Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 36:1089-1091, 2003
25. st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago), December 16-19, 2001 (abstr 113)
26. th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), September 17-20, 2000 (abstr 936)
27. Maertens J, Raad I, Sable C, et al: Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin, amphotericin B, lipid formulations, or azoles, in: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 2000. Washington DC, American Society for Microbiology (abstr 1103)
28. Manavathu EK, Alangaden GJ, Chandrasekar PH: Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 51:1423-1425, 2003
29. Arikan S, Lozano-Chiu M, Paetznick V, et al: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46:245-247, 2002
30. Oshaughnessy EM, Peter J, Walsh TJ: In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002 (abstr 856)
31. Aliff TB, Maslak PG, Jurcic JG, et al: Refractory Aspergillus Pneumonia in patients with acute leukemia. Cancer 97:1025-1032, 2003
32. Lewis RE PR, Chi J, Kontoyiannis DP: Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208-3214, 2002
33. Steinbach WJ, Stevens DA, Denning DW: Combination and sequential antifungal therapy for invasive aspergillosis: Review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 37:S188-S224, 2003 (suppl 3)
34. Marr KA CR, Crippa F, Wald A, et al: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909-917, 2002
35. Hoffman HL, Rathbun RC: Review of the safety and efficacy of voriconazole. Expert Opin Invest Drugs 11:409-429, 2002
36. Espinel-Ingroff: In vitro activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39:954-958, 2001
37. Clancy CJ, Nguyen MH: In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 17:573-575, 1998
38. Pfaller MA MS, Hollis RJ, Jones RN, Sentry Participants Group: Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 46:1032-1037, 2002
39. Dannaoui E, Meletiadis J, Mouton JW, et al: In vitro susceptibilities of zygomycetes to conventional and new anti-fungals. J Antimicrobial Chemother 51:45-52, 2003
40. Wildfeuer A, Paule I, Haberreiter A: In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 41:309-319, 1998
41. Sun Q, Najvar L, Bocanegra R, et al: In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 46:2310-2320, 2002
42. Walsh TJ, Goodman JL, Pappas P, et al: Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45:3487-3496, 2001
43. Imhof A, Walter RB, Schaffner A: Continuous infusion of escalated doses of Amphotericin B Deoxycholate: an open-label observational study. Clin Infect Dis 36:943-951, 2003